Ian Pedley

2.0k total citations
22 papers, 287 citations indexed

About

Ian Pedley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ian Pedley has authored 22 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ian Pedley's work include Prostate Cancer Treatment and Research (14 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Ian Pedley is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Ian Pedley collaborates with scholars based in United Kingdom, Canada and Switzerland. Ian Pedley's co-authors include R. McMenemin, David Sims, Hing Y. Leung, Ian Sudbery, Prabhakar Rajan, Chris P. Ponting, Andreas Heger, Janis Fleming, Joanne Edwards and Ernest Mui and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Ian Pedley

20 papers receiving 286 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian Pedley United Kingdom	7	179	118	81	77	32	22	287
W D Figg United States	5	222 1.2×	147 1.2×	99 1.2×	96 1.2×	17 0.5×	6	357
Susan K. Roethke United States	5	234 1.3×	121 1.0×	127 1.6×	92 1.2×	26 0.8×	6	339
Selena Dixon United Kingdom	2	159 0.9×	105 0.9×	70 0.9×	77 1.0×	10 0.3×	7	248
Elshad Hasanov United States	10	157 0.9×	171 1.4×	105 1.3×	109 1.4×	23 0.7×	36	323
Andrew Krivoshik United States	7	225 1.3×	67 0.6×	162 2.0×	66 0.9×	50 1.6×	11	321
Susan E. Jorge Brazil	7	200 1.1×	112 0.9×	137 1.7×	51 0.7×	20 0.6×	22	303
Eric Xueyu Chen Canada	9	85 0.5×	126 1.1×	187 2.3×	93 1.2×	66 2.1×	54	370
David T. Hoang United States	5	113 0.6×	114 1.0×	76 0.9×	64 0.8×	11 0.3×	7	256
Elisa Biasco Italy	7	187 1.0×	157 1.3×	91 1.1×	156 2.0×	12 0.4×	19	336
Jiumin Liu China	9	124 0.7×	203 1.7×	57 0.7×	160 2.1×	32 1.0×	32	362

Countries citing papers authored by Ian Pedley

Since Specialization

Citations

This map shows the geographic impact of Ian Pedley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Pedley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Pedley more than expected).

Fields of papers citing papers by Ian Pedley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Pedley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Pedley. The network helps show where Ian Pedley may publish in the future.

Co-authorship network of co-authors of Ian Pedley

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Pedley. A scholar is included among the top collaborators of Ian Pedley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Pedley. Ian Pedley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Biran, Adam, Christina Dobson, Colin Rees, et al.. (2025). Healthcare provision for cancer survivors with chronic bowel symptoms post pelvic radiotherapy. “… and then you're kind of cast adrift”: A qualitative study. European Journal of Oncology Nursing. 76. 102895–102895.

Clark, Emma, Holly Fisher, Ruth Wood, et al.. (2023). Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. SHILAP Revista de lepidopterología. 2. 49–49. 4 indexed citations

Biran, Adam, Lisa Durrant, John T. Hancock, et al.. (2023). A Systematic Review of Population-Based Studies of Chronic Bowel Symptoms in Cancer Survivors following Pelvic Radiotherapy. Cancers. 15(16). 4037–4037. 5 indexed citations

Attard, Gerhardt, Louise Brown, Nigel Clarke, et al.. (2021). LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology. 32. S1298–S1298. 5 indexed citations

Jiang, Xue, R. Pearson, Darren Leaning, et al.. (2020). Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. Clinical Oncology. 32(10). e177–e187. 13 indexed citations

Griffiths, William J., J. Frew, R. Chandler, et al.. (2020). Prostate Ultrahypofractionation – Rising to Challenges Presents Opportunities in the COVID-19 Era. Clinical Oncology. 33(1). e90–e90. 1 indexed citations

Clark, Emma, Holly Fisher, Denise Howel, et al.. (2019). Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open. 9(12). e034708–e034708. 6 indexed citations

Khakoo, Shelize, Ian Chau, Ian Pedley, et al.. (2019). ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clinical Colorectal Cancer. 18(4). 280–291.e5. 12 indexed citations

Jiang, Xue, Alexander Burns, J. Frew, et al.. (2019). Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single United Kingdom center.. Journal of Clinical Oncology. 37(7_suppl). 223–223. 2 indexed citations

10.

Frew, J., et al.. (2017). An update on clinical outcome data for a phase II randomized study comparing androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in men with locally advanced/metastatic hormone sensitive prostate cancer.. Journal of Clinical Oncology. 35(6_suppl). 259–259. 1 indexed citations

11.

Pieniążek, Piotr, Rakesh Heer, R. McMenemin, et al.. (2016). Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study.. Journal of Clinical Oncology. 34(2_suppl). 403–403. 2 indexed citations

12.

Rajan, Prabhakar, J. Frew, James M. Wilson, et al.. (2015). Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non–castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 33(8). 337.e1–337.e6. 4 indexed citations

13.

Rajan, Prabhakar, Jacqueline Stockley, Ian Sudbery, et al.. (2014). Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer. 14(1). 977–977. 39 indexed citations

14.

Molife, L. Rhoda, Aurelius Omlin, Robert J. Jones, et al.. (2014). Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer. Future Oncology. 10(2). 219–231. 30 indexed citations

15.

Iqbal, Muhammad Shahid, Ian Pedley, J. Frew, et al.. (2014). Delays in the diagnosis and treatment of muscle invasive bladder cancer: A pilot project mapping the pathway. Journal of Clinical Urology. 8(4). 246–251. 2 indexed citations

16.

Rajan, Prabhakar, Ian Sudbery, Ernest Mui, et al.. (2013). Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. European Urology. 66(1). 32–39. 114 indexed citations

17.

Wilson, James M., Albiruni Ryan Abdul Razak, J. Frew, et al.. (2012). Clinical Outcomes of a Phase II Open-labelled, Randomised Study Investigating the Tolerability and Efficacy of Anti-androgen Manipulation versus Taxotere and Anti-androgen Manipulation in Patients with Hormone Naive High Risk/Metastatic Prostate Cancer. Clinical Oncology. 24(2). 156–157.

18.

Robinson, Stuart, Derek Manas, Ian Pedley, Derek A. Mann, & Steven A. White. (2009). Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surgical Oncology. 20(2). 57–72. 27 indexed citations

19.

Pedley, Ian. (2002). Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate. Surgical Oncology. 11(1-2). 25–34. 6 indexed citations

20.

Watters, John W., et al.. (2001). The Development of a Protocol for the Use of 5–HT3 Antagonists in Chemotherapy-Induced Nausea and Vomiting. Clinical Oncology. 13(6). 422–426. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact